In order to determine if broader epigenetic therapies could “unlock” glioma initiating cells (GIC) from a dedifferentiated state, we treated both wild-type and mutant IDH cell lines with DAC and/or IDH inhibitor AGI-5198. Here, IDH1 is linked to central nervous system cancer.